melanoma
one
notori
type
cancer
known
us
studi
indic
melanoma
resist
type
chemotherapi
exploit
intrins
apoptosi
resist
reprogram
prolif
pathway
melanoma
develop
recent
studi
show
melanoma
cell
abil
delay
apoptot
death
paraphenylenediamin
ppd
long
known
essenti
compon
perman
hair
dye
long
time
ppd
use
textil
leather
hair
dye
industri
ppd
hair
dye
report
pure
serv
extern
dye
agent
sporad
side
effect
human
mous
model
ppd
report
moreov
experiment
design
report
correl
reallif
use
effect
ppd
skin
keratinocyt
thoroughli
investig
group
ppd
convert
brandrowski
base
autoxid
selfconjug
besid
shown
keratinocyt
contain
nacetyltransferas
modifi
ppd
mono
dinacetyl
therebi
modul
toxic
effect
ppd
investig
differ
cell
type
found
caus
apoptosi
via
ro
howev
littl
done
demonstr
consequ
ppd
treatment
melanocyt
melanoma
cell
report
investig
effect
ppd
melanin
produc
human
mous
melanoma
cell
line
respect
first
time
demonstr
ppd
caus
disrupt
mitochondri
membran
potenti
gener
ro
lead
apoptosi
cell
primarili
via
activ
caspas
studi
use
mice
melanoma
model
show
ppd
induc
apoptosi
inhibit
tumour
growth
fetal
bovin
serum
fb
dulbecco
modifi
eagl
medium
dmem
trypsinedta
antibiot
antimycot
agent
obtain
life
technolog
usa
monoclon
antiparp
antibodi
antiactin
antibodi
purchas
cell
signal
technolog
usa
anticaspas
anticaspas
antibodi
cell
signal
technolog
usa
gener
gift
dr
chitra
mondal
scientist
antijnk
antibodi
caspas
inhibitor
c
caspas
inhibitor
c
pan
caspas
inhibitor
c
dr
pijush
k
da
chief
scientist
indian
institut
chemic
biolog
iicb
kolkata
india
antibid
antibodi
abcam
usa
kind
gift
dr
p
c
sil
depart
molecular
medicin
bose
institut
kolkata
dichlorodihydrofluorescein
diacet
dcfhda
kind
gift
dr
ghosh
depart
biochemistri
univers
calcutta
alkalin
phosphat
conjug
secondari
antibodi
mous
rabbit
rais
goat
respect
mtt
base
cell
count
proteas
inhibitor
cocktail
nacetyl
cystein
nac
ppd
glutathion
reductas
glutathion
nadph
edta
glutathion
disulfid
gssg
dtnb
reagent
state
otherwis
purchas
sigmaaldrich
compani
usa
alexa
goat
antirabbit
igg
purchas
life
technolog
usa
cell
deriv
human
mous
melanoma
respect
use
paper
purchas
nation
centr
cell
scienc
pune
india
cell
line
cultur
dulbecco
modifi
eagl
media
contain
fetal
bovin
serum
life
technolog
usa
humidifi
atmospher
contain
air
stock
solut
ppd
mgml
dissolv
dmso
differ
concentr
prepar
cultur
medium
final
dmso
concentr
type
cell
seed
densiti
mm
plate
grown
h
confluenc
cultur
medium
replac
new
medium
ad
differ
concentr
ppd
treat
cell
indic
time
point
dmso
use
vehicl
control
viabil
assay
use
mtt
cellswel
seed
plate
hour
follow
cell
treat
ppd
dmso
indic
treatment
media
well
replac
fresh
media
follow
mtt
reagent
sigma
absorb
read
collect
interv
one
hour
four
hour
use
biorad
imark
micropl
reader
studi
use
caspas
inhibitor
procedur
use
similar
describ
except
cell
pretreat
caspas
inhibitor
hour
treat
hour
indic
concentr
ppd
parallel
experi
mtt
assay
done
accur
determin
number
viabl
cell
absorb
among
cell
grown
hour
valu
subtract
valu
obtain
mtt
assay
use
caspas
inhibitor
correct
valu
set
without
inhibitor
comput
use
follow
equat
chang
viabl
p
absorb
hour
stand
ppd
treat
cell
pretreat
caspas
inhibitor
p
stand
cell
treat
ppd
indic
absorb
hour
cell
seed
correct
valu
chang
viabl
cell
thu
obtain
plot
respect
concentr
ppd
inhibitor
concentr
use
follow
caspas
inhibitor
caspas
inhibitor
pan
caspas
inhibitor
cell
treat
inhibitor
show
advers
effect
total
cellular
protein
content
control
ppd
treat
cell
measur
cell
boil
protein
load
buffer
minut
protein
sampl
subject
sdspage
gel
transfer
onto
pvdf
membran
membran
block
bsa
pb
h
room
temperatur
shake
follow
overnight
incub
respect
primari
antibodi
alkalin
phosphatas
conjug
correspond
secondari
antibodi
pb
use
h
room
temperatur
shake
end
incub
antibodi
membran
wash
extens
pb
contain
membran
develop
nbtbcip
system
per
manufactur
protocol
gsh
gssg
measur
accord
protocol
akerboom
sie
crude
cellfre
extract
ad
equal
volum
contain
mm
edta
incub
ice
minut
centrifug
g
minut
result
supernat
neutral
koh
contain
hepe
centrifug
g
minut
supernat
use
estim
total
glutathion
gsh
measur
grdepend
dtnb
reduct
spectrophotometr
nm
neutral
extract
treat
vv
hour
room
temperatur
use
gssg
estim
use
method
glutathion
reductas
gr
activ
crude
cellfre
extract
determin
measur
nadph
oxid
spectrophotometr
nm
catalas
activ
measur
decreas
absorb
nm
spectrophotometr
frequenc
apoptot
cell
detect
annexin
vfitc
life
technolog
cell
incub
differ
concentr
ppd
variou
time
point
incub
cell
trypsin
collect
wash
pb
resuspend
bind
buffer
hepe
mm
ph
mm
nacl
mm
concentr
cellsml
case
tumour
cell
wash
directli
resuspend
bind
buffer
annexin
vfitc
dapi
ad
incub
dark
min
cell
subject
flow
cytometr
analysi
bd
facsvers
bd
bioscienc
use
bd
facsuit
softwar
least
event
record
repres
dot
plot
case
caspas
inhibitor
studi
prepar
set
cell
first
one
control
cell
second
ppd
treat
cell
third
cell
ppd
treat
pretreat
caspas
inhibitor
basal
earli
late
apoptosi
valu
first
subtract
respect
valu
group
modifi
valu
use
calcul
reduct
apoptosi
number
cell
posit
annexin
vfitc
annexin
vfitc
dapi
consid
earli
late
apoptot
cell
respect
ppd
treatment
cell
harvest
rins
pb
cell
pellet
fix
ethanol
overnight
wash
twice
pb
cell
incub
rnase
mgml
minut
stain
use
propidium
iodid
pi
pb
follow
incub
rt
dark
min
sampl
analys
bd
facsvers
bd
bioscienc
use
bd
facsuit
softwar
least
event
analys
record
ppd
treat
untreat
cell
analys
mitochondri
membran
potenti
use
jc
dye
life
technolog
accord
manufactur
instruct
brief
upon
complet
incub
cell
trypsin
collect
dmem
cell
stain
jc
min
subsequ
cell
wash
resuspend
pb
prior
flow
cytometr
analysi
bd
facsaria
iii
bd
bioscienc
use
bd
facsdiva
softwar
jc
stain
normal
polar
cell
show
high
fluoresc
pe
channel
pe
fluoresc
due
presenc
jc
aggreg
insid
mitochondria
low
fluoresc
fitc
channel
fitc
fluoresc
due
monomer
jc
present
cell
case
cell
contain
depolar
mitochondria
observ
revers
least
event
analys
record
data
repres
percent
chang
cell
depolar
mmp
use
bd
fitc
brdu
flow
kit
determin
percentag
cell
phase
follow
manufactur
protocol
brief
end
ppd
treatment
cell
incub
brdu
minut
fix
bd
cytofixcytoperm
buffer
cell
treat
bd
permeabil
buffer
plu
cell
incub
bd
cytofixcytoperm
buffer
follow
dnase
treatment
expos
brdu
epitop
immunofluoresc
stain
done
use
fluorochrom
conjug
antibrdu
antibodi
final
cell
stain
follow
analysi
bd
facsvers
use
bd
facsuit
softwar
least
event
record
analys
intracellular
product
ro
determin
flow
cytometri
briefli
cell
trypsin
ppd
treatment
collect
wash
twice
pb
cell
load
dichlorodihydrofluorescein
diacet
dcfhda
life
technolog
incub
min
dark
case
tumour
cell
wash
load
probe
cell
wash
resuspend
pb
sampl
analys
facsaria
iii
bd
bioscienc
use
bd
facsdiva
softwar
least
event
analys
record
viabl
cell
incorpor
deacetyl
dcfhda
nonfluoresc
dcfh
turn
quantit
oxid
ro
produc
fluoresc
dcf
ppd
treatment
show
posit
increas
median
green
fluoresc
henc
quantiti
ro
ro
deplet
studi
cell
pretreat
hour
mm
glutathion
nac
respect
standard
cell
growth
condit
hour
ppd
introduc
medium
hour
case
caspas
inhibitor
studi
pretreat
done
mention
earlier
cell
inject
subcutan
sc
right
flank
swissalbino
mice
tumour
gener
care
mainten
anim
done
adher
guidelin
institut
anim
care
use
committe
tumour
took
approxim
week
becom
visibl
anim
divid
four
group
n
n
one
group
contain
mice
tumour
one
tumour
bear
mice
group
left
untreat
two
group
tumour
bear
mice
given
ip
inject
day
ppd
per
wilcoxon
method
flow
cytometr
experi
singl
cell
suspens
made
ppd
treat
untreat
mice
tumour
toxic
studi
anim
divid
three
group
n
first
group
receiv
vehicl
normal
salin
ip
second
third
group
receiv
ppd
dose
day
dose
dose
resp
ip
week
food
water
intak
anim
observ
period
twentyfour
hour
last
dose
day
blood
collect
group
cardiac
punctur
estim
haematolog
serum
biochem
paramet
explor
effect
ppd
melanoma
cell
treat
cell
differ
concentr
ppd
variou
time
point
initi
investig
phase
contrast
microscop
show
adher
cell
number
decreas
increas
concentr
ppd
time
taken
complet
loss
adher
cell
observ
approxim
hour
mgml
ppd
respect
quantifi
cytotox
effect
carri
mtt
base
cell
viabil
assay
use
cell
treat
increas
concentr
ppd
hour
hour
time
ppd
show
cytotox
effect
cell
line
figur
b
show
cell
remain
viabl
cell
line
treat
ppd
treatment
ppd
reduc
viabl
cell
case
respect
treat
ppd
cell
found
sensit
time
point
dmso
use
vehicl
control
show
effect
cell
investig
whether
cytotox
compound
specif
paraisom
carri
similar
mtt
assay
use
melanoma
cell
treat
differ
concentr
opd
figur
c
clearli
indic
cell
death
observ
set
treat
similar
concentr
opd
hour
treatment
hour
howev
cytotox
effect
extent
much
less
ppd
determin
cytotox
effect
ppd
melanocyt
cultur
investig
effect
melanoma
tumour
mice
assess
system
cytotox
ppd
mice
two
group
swissalbino
mice
male
week
old
intraperiton
ip
inject
ppd
mgkg
interv
day
throughout
period
week
treatment
mice
appear
quit
activ
untreat
one
data
shown
therefor
monthlong
periton
administr
high
mgkg
ppd
show
sign
toxic
swissalbino
mice
explor
cytotox
effect
ppd
melanoma
tumour
subcutan
sc
inject
cell
right
flank
swissalbino
mice
tumour
gener
two
week
later
tumour
visibl
ip
inject
mgkg
ppd
given
mice
bear
tumour
result
show
ppd
treatment
mice
carri
melanoma
tumour
result
reduct
tumour
mass
reveal
tumour
size
figur
c
correspond
decreas
bodi
weight
figur
b
cell
deriv
ppd
treat
tumour
show
increas
apoptosi
evid
annexin
v
base
flow
cytometr
analysi
data
shown
report
toxic
effect
ppd
rodent
model
studi
side
effect
ppd
report
mostli
base
unrealist
design
feed
topic
applic
subcutan
inject
high
dosag
ppd
besid
meagr
percentag
human
popul
report
allerg
ppd
concentr
ppd
petrolatum
report
reliabl
respect
contact
dermat
moreov
concentr
rang
sever
standard
anticanc
drug
administ
intraven
lie
mm
fda
approv
drug
oncolog
maximum
concentr
ppd
use
equival
littl
less
mm
therefor
accord
publish
report
concentr
ppd
use
presum
safe
effect
reduc
melanoma
tumour
mass
mice
verifi
perform
haematolog
serum
biochem
paramet
measur
treat
mice
along
control
week
studi
reveal
mortal
toxic
symptom
biochem
chang
major
organ
test
group
treat
higher
select
dose
mgkg
ppd
signific
differ
found
bodi
weight
gainloss
weight
major
organ
haematolog
biochem
paramet
control
test
group
shown
tabl
understand
mechan
cell
death
ppd
treatment
first
ask
whether
apoptosi
address
test
activ
parp
wellknown
marker
apoptosi
lysat
cell
treat
indic
concentr
ppd
differ
time
point
analys
immunoblot
use
specif
antibodi
parp
figur
show
activ
form
parp
kda
present
treat
cell
lysat
lane
cleav
form
parp
untreat
sampl
lane
much
less
intens
compar
treat
sampl
indic
presenc
natur
occur
apoptot
cell
popul
also
clear
result
either
proport
fulllength
parp
reduc
compar
lane
proport
activ
form
parp
increas
compar
lane
increas
concentr
ppd
treatment
apoptosi
also
confirm
flow
cytometri
use
annexin
vfitc
figur
b
show
apoptot
cell
apoptot
cell
treat
ppd
respect
hour
percent
live
earli
late
apoptot
cell
control
treat
sampl
illustr
tabl
tabl
also
consist
number
particl
determin
flow
cytometr
cell
cycl
assay
clear
correl
observ
apoptot
cell
number
estim
two
differ
method
note
cell
sensit
cell
moreov
number
apoptot
cell
corrobor
decreas
live
cell
determin
mtt
assay
cp
figur
b
tabl
multipl
instanc
upon
treatment
cytotox
agent
cell
get
arrest
specif
cell
cycl
stage
undergo
apoptosi
therefor
also
investig
role
ppd
cell
cycl
progress
flow
cytometr
result
show
cell
specif
treat
low
concentr
ppd
earli
time
point
get
arrest
phase
block
go
away
time
figur
b
treatment
higher
concentr
ppd
unabl
show
phase
arrest
reason
pattern
clear
moment
verifi
arrest
phase
brdu
incorpor
experi
done
use
flow
cytometri
data
also
confirm
block
phase
cell
treat
low
concentr
ppd
figur
b
similar
pattern
also
found
case
cell
data
shown
apoptot
cell
activ
parp
could
result
two
diverg
pathway
extrins
intrins
activ
caspas
respect
signatur
delin
possibl
use
cell
lysat
prepar
show
activ
parp
figur
check
presenc
activ
form
caspas
use
immunoblot
interestingli
shorter
time
point
hour
caspas
get
activ
figur
lane
activ
caspas
seen
sampl
treat
hour
figur
b
lane
known
activ
caspas
may
lead
activ
bid
famili
protein
turn
destabil
mitochondri
membran
initi
caspas
mediat
intrins
pathway
explor
possibl
check
decreas
fulllength
bid
cell
lysat
use
western
blot
antibid
antibodi
hour
time
point
amount
bid
remain
unalt
figur
lane
gradual
decreas
observ
sampl
treat
increas
concentr
ppd
hour
figur
b
lane
appar
result
extrins
pathway
activ
intrins
one
ppd
treat
melanoma
cell
pharmacolog
inhibitor
caspas
use
identifi
primari
caspas
activ
respons
initi
apoptosi
perform
experi
use
differ
caspas
inhibitor
assess
cell
viabil
apoptosi
respons
ppd
treatment
cell
incub
caspas
inhibitor
treat
ppd
hour
cell
viabil
measur
mtt
base
assay
result
clearli
demonstr
cell
pretreat
caspas
inhibitor
show
signific
increas
viabl
cell
figur
decreas
dead
cell
number
figur
upon
ppd
treatment
compar
cell
without
inhibitor
figur
protect
effect
inhibitor
caspas
ppd
respect
obviou
effect
inhibitor
cell
treat
lesser
ppd
inhibitor
caspas
show
protect
ppd
induc
cell
death
pan
inhibitor
caspas
significantli
prevent
cell
death
induc
higher
dosag
ppd
particular
protect
effect
caspas
inhibitor
apoptosi
also
verifi
flow
cytometri
experi
number
annexin
v
posit
cell
respons
ppd
hour
reduc
earli
late
apoptosi
respect
pretreat
caspas
inhibitor
compar
inhibitor
set
result
demonstr
larg
extent
ppd
induc
apoptot
death
melanoma
cell
mediat
activ
caspas
shown
ppd
treatment
longer
time
led
format
tbid
cell
tbid
known
destabil
mitochondri
membran
potenti
mmp
test
whether
mmp
treat
cell
gone
chang
flow
cytometr
measur
done
use
jc
ratiometr
fluoresc
dye
oppos
result
show
tbid
format
data
show
cell
treat
ppd
low
hour
undergon
decreas
mmp
figur
evid
respons
ppd
treatment
mmp
much
suscept
activ
either
caspas
bid
thu
presum
direct
consequ
treatment
demonstr
disrupt
mmp
caus
ro
gener
dcfhda
stain
use
uncov
statu
ro
control
treat
cell
flow
cytometri
result
show
hour
ppd
treatment
ro
gener
cell
type
neglig
data
shown
clear
cell
show
signific
increas
amount
ro
hour
treatment
figur
trend
continu
treat
sampl
data
shown
cell
isol
ppd
treat
mice
tumour
also
show
substanti
increas
ro
level
compar
untreat
tumour
data
shown
biochem
experi
also
use
authent
find
reduct
ratio
reduc
oxid
glutathion
gsh
gssg
increas
activ
enzym
glutathion
reductas
gr
catalas
commonli
use
standard
indic
cellular
oxid
stressro
result
measur
demonstr
catalas
gr
activ
increas
respect
lysat
cell
treat
ppd
hour
tabl
substanti
reduct
amount
gsh
result
decreas
gsh
gssg
ratio
ppd
treat
cell
biochem
line
evid
conjunct
flow
cytometr
data
strongli
indic
ppd
treatment
actual
impart
strong
oxid
stress
cell
point
use
nac
glutathion
gsh
pretreat
ppd
exposur
valid
effect
ro
apoptosi
melanoma
cell
clear
tabl
pretreat
specif
nac
decreas
amount
ro
induc
ppd
pretreat
also
reduc
extent
apoptosi
ppd
treat
cell
tabl
result
strongli
establish
correl
ro
gener
apoptot
death
ppd
treat
melanoma
cell
furthermor
investig
whether
ppd
mediat
deplet
mmp
depend
ro
similar
experi
nac
done
flow
cytometri
analysi
use
jc
confirm
mmp
destabil
independ
ro
gener
indic
ro
product
downstream
disrupt
mmp
howev
increas
ro
respons
ppd
could
obliter
block
activ
caspas
data
shown
suggest
fact
stimul
ro
ppd
treat
cell
occur
independ
activ
caspas
although
ppd
induc
apoptot
death
melanoma
cell
concurr
initi
loss
mmp
activ
caspas
gener
ro
inhibit
caspas
activ
effect
ro
product
sequestr
nac
also
could
disrupt
mmp
howev
suppress
ro
nac
show
mark
reduct
ppd
mediat
apoptot
death
vitro
tabl
observ
conjunct
fact
loss
mmp
occur
much
earlier
induct
ro
clearli
indic
mitochondria
one
primari
target
ppd
see
text
activ
caspas
took
place
initi
loss
mmp
gener
ro
suggest
mitochondria
possibl
role
activ
shown
elsewher
seem
activ
caspas
stimul
ro
take
place
via
two
independ
pathway
may
subsequ
posit
feedback
inde
report
show
similar
interact
ro
activ
caspas
although
disrupt
mmp
occur
earli
respons
lower
concentr
ppd
activ
caspas
observ
cell
treat
higher
concentr
ppd
hour
explain
cite
exampl
previou
report
state
loss
mmp
especi
small
reduc
substrat
necessarili
lead
releas
cytochrom
c
case
ppd
cell
permeabl
reduc
agent
may
caus
disrupt
mmp
without
appreci
releas
cytochrom
c
evid
activ
caspas
time
skin
cancer
dread
malign
tumour
virtu
strong
resist
known
chemotherapi
incid
skin
cancer
rise
especi
among
caucasian
popul
case
fatal
melanoma
probabl
highest
among
skin
cancer
also
among
type
cancer
present
highdos
recent
cytotox
tlymphocyt
antigen
work
activ
immun
system
therapi
result
longterm
diseasefre
interv
despit
decad
systemat
therapeut
investig
use
cytotox
immunolog
molecularli
target
agent
surviv
rate
among
treat
patient
advanc
melanoma
discourag
studi
show
first
time
human
mous
melanoma
cell
undergo
ro
mediat
apoptot
death
treat
ppd
opd
vitro
importantli
periton
inject
mgkg
ppd
inhibit
growth
rate
induc
melanoma
tumour
mice
figur
howev
monthlong
periton
administr
high
mgkg
ppd
show
sign
toxic
swissalbino
mice
total
number
annexin
v
posit
cell
increas
tumour
ppd
treat
mice
observ
substanti
vitro
find
ppd
mediat
apoptot
death
melanoma
cell
taken
togeth
observ
suggest
ppd
mediat
apoptot
destruct
human
mous
melanoma
cell
primarili
via
loss
mmp
activ
caspas
ro
gener
undertaken
experi
get
deeper
insight
mechan
apoptot
death
melanoma
cell
ppd
studi
creat
platform
develop
agent
success
kill
melanoma
cell
otherwis
resist
standard
chemotherapeut
